癌症患者的收入估计超过了INKT. INKT beats earnings estimates with durable cancer remissions.

据MiNK Therapeutics (INKT) 的报道,季度收益超过预期,癌症的持续缓解和ARDS患者生存率改善. MiNK Therapeutics (INKT) reported quarterly earnings exceeding expectations, citing durable cancer remissions and improved survival rates in ARDS patients. 由于公司将现金1640万美元用于延长跑道到2026年,因此面临1250万美元的损失,并且可能需要进一步融资进行更大的试验. With $16.4 million in cash extending its runway to 2026, the company faces a $12.5 million loss and may need further financing for larger trials. 股票的收益很小, 保持了分析师一致认为"持有". The stock saw minimal gains, maintaining a consensus "Hold" rating from analysts.